The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

Leisha A. Emens(Johns Hopkins University), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust)

Cancer Immunology Research

May 1, 2015

10.1158/2326-6066.cir-15-0064

Cited by 814

Related Papers

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

|New England Journal of Medicine|2008|2.3k

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

|The Lancet Oncology|2013|728

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|604

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

|Annals of Oncology|2021|453

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374